CO6321271A2 - Derivados de urea macrociclicos y de sulfamida como inhibidores de tafla - Google Patents

Derivados de urea macrociclicos y de sulfamida como inhibidores de tafla

Info

Publication number
CO6321271A2
CO6321271A2 CO10151420A CO10151420A CO6321271A2 CO 6321271 A2 CO6321271 A2 CO 6321271A2 CO 10151420 A CO10151420 A CO 10151420A CO 10151420 A CO10151420 A CO 10151420A CO 6321271 A2 CO6321271 A2 CO 6321271A2
Authority
CO
Colombia
Prior art keywords
macrociclic
sulfamide
urea derivatives
inhibitors
tafla inhibitors
Prior art date
Application number
CO10151420A
Other languages
English (en)
Spanish (es)
Inventor
Christopher Kallus
Mark Broenstrup
Andreas Evers
Michael Wagner
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of CO6321271A2 publication Critical patent/CO6321271A2/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D273/00Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/01Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having one nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/06Antiarrhythmics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D267/00Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D273/00Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00
    • C07D273/02Heterocyclic compounds containing rings having nitrogen and oxygen atoms as the only ring hetero atoms, not provided for by groups C07D261/00 - C07D271/00 having two nitrogen atoms and only one oxygen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Communicable Diseases (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CO10151420A 2008-06-06 2010-12-01 Derivados de urea macrociclicos y de sulfamida como inhibidores de tafla CO6321271A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08290520 2008-06-06

Publications (1)

Publication Number Publication Date
CO6321271A2 true CO6321271A2 (es) 2011-09-20

Family

ID=39800716

Family Applications (1)

Application Number Title Priority Date Filing Date
CO10151420A CO6321271A2 (es) 2008-06-06 2010-12-01 Derivados de urea macrociclicos y de sulfamida como inhibidores de tafla

Country Status (34)

Country Link
US (5) US8580777B2 (https=)
EP (1) EP2300462B1 (https=)
JP (1) JP5531011B2 (https=)
KR (1) KR101673886B1 (https=)
CN (1) CN102056922B (https=)
AR (1) AR072007A1 (https=)
AU (1) AU2009254257B2 (https=)
BR (1) BRPI0913349A2 (https=)
CA (1) CA2726554C (https=)
CL (1) CL2009001358A1 (https=)
CO (1) CO6321271A2 (https=)
CR (1) CR11807A (https=)
CY (1) CY1115604T1 (https=)
DK (1) DK2300462T3 (https=)
DO (1) DOP2010000363A (https=)
EC (1) ECSP10010655A (https=)
ES (1) ES2494390T3 (https=)
HN (1) HN2010002558A (https=)
HR (1) HRP20140787T1 (https=)
IL (1) IL209772A (https=)
MA (1) MA32322B1 (https=)
MX (1) MX2010012793A (https=)
NI (1) NI201000203A (https=)
NZ (1) NZ589671A (https=)
PL (1) PL2300462T3 (https=)
PT (1) PT2300462E (https=)
RU (1) RU2502736C2 (https=)
SI (1) SI2300462T1 (https=)
SV (1) SV2010003747A (https=)
TW (1) TWI455928B (https=)
UA (1) UA104002C2 (https=)
UY (1) UY31868A (https=)
WO (1) WO2009146802A1 (https=)
ZA (1) ZA201007719B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2300462T1 (sl) 2008-06-06 2014-09-30 Sanofi Makrociklični sečninski in sulfamidni derivati kot inhibitorji za TAFIa
EA018502B1 (ru) 2008-06-23 2013-08-30 Астразенека Аб Новые гетероциклические карбоксамиды и фармацевтические композиции, содержащие их
US8354444B2 (en) 2008-09-18 2013-01-15 Hoffmann-La Roche Inc. Substituted pyrrolidine-2-carboxamides
HUE034118T2 (en) * 2012-03-06 2018-01-29 Pfizer Macrocyclic derivatives for the treatment of proliferative diseases
CA2914533A1 (en) * 2013-06-10 2014-12-18 Sanofi Macrocyclic urea derivatives as inhibitors of tafia, their preparation and their use as pharmaceuticals
UY35809A (es) * 2013-11-05 2015-05-29 Bayer Pharma AG (aza)piridopirazolopirimidinonas e indazolopirimidinonas y sus usos
CN103755852B (zh) * 2013-12-18 2015-12-09 湖北大学 线型聚苯乙烯支载(4s)-(4’-氧苄基)-2-正丁基环磺酰胺及其制备方法和用途
CN106631832A (zh) * 2016-10-08 2017-05-10 帕潘纳(北京)科技有限公司 一种氨基醚类化合物的制备方法
US10411291B2 (en) * 2017-03-22 2019-09-10 Nanotek Instruments, Inc. Multivalent metal ion battery having a cathode layer of protected graphitic carbon and manufacturing method

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU667995B2 (en) 1993-02-15 1996-04-18 Bayer Aktiengesellschaft New pseudopeptides having an antiviral action
TW394760B (en) 1993-09-07 2000-06-21 Hoffmann La Roche Novel Carboxamides, process for their preparation and pharmaceutical composition containing the same
US5888971A (en) * 1996-02-20 1999-03-30 Ortho Pharmaceutical Corporation, Inc. Macrocyclic peptides useful in the treatment of thrombin related disorders
CA2298601A1 (en) 1997-08-28 1999-03-11 Pharmacia & Upjohn Company Inhibitors of protein tyrosine phosphatase
US6124278A (en) * 1998-04-03 2000-09-26 The Regents Of The University Of California Acylbenzoxazines for enhancing synaptic response
US6482921B1 (en) 1999-01-28 2002-11-19 Essential Therapeutics, Inc. Uridyl peptide antibiotic (UPA) derivatives, their synthesis and use
DE60042585D1 (de) * 2000-02-29 2009-09-03 Univ Firenze 3-Aza-6,8-dioxabicycloÄ3.2.1Üoctane und Analoga sowie diese enthaltende kombinatorische Bibliotheken
DE102004020186A1 (de) * 2004-04-22 2005-11-17 Aventis Pharma Deutschland Gmbh Heterocyclylessigsäuren als Inhibitoren von TAFla
HRP20150514T1 (hr) 2006-12-06 2015-09-11 Sanofi DERIVATI SULFAMIDA KAO INHIBITORI TAFIa
SI2300462T1 (sl) 2008-06-06 2014-09-30 Sanofi Makrociklični sečninski in sulfamidni derivati kot inhibitorji za TAFIa

Also Published As

Publication number Publication date
US8580777B2 (en) 2013-11-12
ZA201007719B (en) 2011-07-27
DK2300462T3 (da) 2014-08-18
HRP20140787T1 (hr) 2014-11-21
NZ589671A (en) 2012-03-30
IL209772A (en) 2016-04-21
ECSP10010655A (es) 2011-01-31
US9126955B2 (en) 2015-09-08
US9688645B2 (en) 2017-06-27
SV2010003747A (es) 2011-03-15
CR11807A (es) 2011-02-16
US20110178130A1 (en) 2011-07-21
JP2011521981A (ja) 2011-07-28
US20140039011A1 (en) 2014-02-06
PT2300462E (pt) 2014-08-05
JP5531011B2 (ja) 2014-06-25
MX2010012793A (es) 2010-12-14
DOP2010000363A (es) 2010-12-15
BRPI0913349A2 (pt) 2015-11-24
US20160251324A1 (en) 2016-09-01
HN2010002558A (es) 2012-08-28
CY1115604T1 (el) 2017-01-04
CA2726554C (en) 2015-02-24
RU2502736C2 (ru) 2013-12-27
US9309207B2 (en) 2016-04-12
EP2300462A1 (de) 2011-03-30
TWI455928B (zh) 2014-10-11
RU2010154089A (ru) 2012-07-20
WO2009146802A1 (de) 2009-12-10
UY31868A (es) 2010-01-05
MA32322B1 (fr) 2011-05-02
CN102056922A (zh) 2011-05-11
AU2009254257A1 (en) 2009-12-10
CA2726554A1 (en) 2009-12-10
HK1152936A1 (en) 2012-03-16
UA104002C2 (ru) 2013-12-25
CN102056922B (zh) 2013-11-20
EP2300462B1 (de) 2014-05-21
AR072007A1 (es) 2010-07-28
TW201008917A (en) 2010-03-01
NI201000203A (es) 2011-09-29
US20160024033A1 (en) 2016-01-28
SI2300462T1 (sl) 2014-09-30
US8722655B2 (en) 2014-05-13
AU2009254257B2 (en) 2013-11-21
ES2494390T3 (es) 2014-09-15
US20140206760A1 (en) 2014-07-24
KR20110020795A (ko) 2011-03-03
PL2300462T3 (pl) 2014-10-31
KR101673886B1 (ko) 2016-11-08
IL209772A0 (en) 2011-02-28
CL2009001358A1 (es) 2009-11-27

Similar Documents

Publication Publication Date Title
CO6321271A2 (es) Derivados de urea macrociclicos y de sulfamida como inhibidores de tafla
CO6390069A2 (es) Compuestos de piridina sustituida unida por puente a un heterociclo, como inhibidores de la vía de señalización hedgehog.
MX2018006148A (es) Inhibidores de cxcr2.
NI201100166A (es) Derivados de benzofuranilo utilizados como inhibidores de glucoquinasa
BR112018006080A2 (pt) novos compostos bicíclicos como inibidores de dupla ação de atx/ca
EA201200917A1 (ru) Пролекарства ингибиторов плазменного калликреина
GT200900186A (es) Compuestos carboxamida y su uso como inhibidores de calpaína
MX374439B (es) Compuesto de piridona como inhibidor de c-met
EA201190227A1 (ru) Оксазолзамещенные индазолы в качестве ингибиторов pi3-киназ
BR112013021896A2 (pt) inibidores de serina/treonina cinase
UY32384A (es) Nuevas bencenosulfonamidas como bloqueadores de canales de calcio
MX2017008048A (es) Derivados de 5-[(piperazin-1-il)-3-oxopropil]-imidazolidin-2,4-dio na como inhibidores de desintegrina y metaloproteinasa con motivos de trombospondina (adamts) para el tratamiento de osteoartritis.
NI200600217A (es) Derivados de imidazol utilizados como inhibidores de tafia
MX372740B (es) Derivado de 2,4-diaminopirimidina biciclico fusionado como un inhibidor dual de alk y fak.
BR112017026682A2 (pt) novos compostos bicíclicos como inibidores de dupla ação de atx/ca
CL2011002911A1 (es) Compuestos derivados de benzamidas, inhibidores de serina proteasa; composición farmacéutica; uso del compuesto para tratar cáncer.
MX2018005045A (es) Inhibidores de factor xia.
UA108878C2 (ru) Ингибиторы протеинтирозинкиназной активности
BR112017009629A2 (pt) triazolo [4,5-d] pirimidinas como agonistas do receptor canabinoide 2
NZ706418A (en) Azaquinazoline carboxamide derivatives
NO20092246L (no) Urea og sulfamidderivater som tafiainhibitorer
BR112014016803A2 (pt) amidas macrocíclicas como inibidoras de protease
MX373636B (es) Compuestos de azetidiniloxifenilpirrolidina.
MX2015011567A (es) Halogeno-pirazoles como inhibidores de trombina.
UY30760A1 (es) Derivados de urea y derivados de sulfamida en calidad de inhibidores de tafia

Legal Events

Date Code Title Description
FG Application granted